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Efficacy and acceptability of pharmacological interventions for the treatment of antipsychotic-related 
weight gain and metabolic abnormalities 
A systematic review and network meta-analysis 
 
Abstract 
Antipsychotic treatment (AP) is associated with metabolic abnormalities including weight gain. Targeting 
AP-associated weight gain, several pharmacological interventions have been investigated. Nevertheless, 
there is barely evidence for comparative efficacy and acceptability of these interventions. In this study, we 
will systematically review evidence for weight loss reducing agents in AP-medicated patients and compare 
outcomes of interventions in terms of efficacy and acceptability. Only blinded, randomized controlled 
studies of adjunctive agents for weight loss reduction in AP-medicated patients will be included. Pooled 
data will be analysed using a network meta-analysis. The primary outcomes will be measured as the mean 
difference for weight change and as odds ratio for treatment discontinuations due to any cause. Further 
analyses will encompass an additive model to evaluate the influence of components such as lifestyle 
counselling, exercise and diet. Subgroup, meta-regression and sensitivity analyses will focus on the impact 
of factors such as age, sex, body mass index, AP dose and type of AP. Results will be published in a peer-
reviewed journal.  
  
Introduction 
Although older reports are available, the study of weight gain related to antipsychotics has been 
particularly extensive in the past two decades. Almost all widely prescribed antipsychotics have been 
related to weight gain (1-4). This association is of particular clinical interest as it is connected to major 
health risks (5, 6). The mortality gap is a term established to described the reduced life expectancy in 
patients with severe mental illnesses compared to the general population (7, 8). There are various factors 
linked to this excess mortality; lifestyle aspects, such as smoking, unhealthy eating and lack of physical 
exercise seem to have a crucial impact (9, 10). The role of antipsychotics with their adverse weight and 
metabolic effects is also related to physical health risk factors (11). When dealing with antipsychotic-
associated weight gain, various types of interventions including pharmacological agents have been 
investigated. Several of these agents have received considerable attention. Nevertheless, no head-to-head 
comparisons are available and these strategies are often off-label. Thus, there is the need to provide 
evidence about the comparative efficacy and acceptability of these pharmacological interventions as well 
as the confounding factors affecting treatment response.   
Aim of this study is to systematically review evidence for pharmacologic interventions targeting 
cardiometabolic abnormalities in antipsychotic-treated patients and compare efficacy and acceptability of 
these interventions. 
 
Methods 
Search strategy 
We will perform a systematic review and network meta-analysis (NMA). Our search will include MEDLINE, 
Embase and the US National Institutes of Health Trials Registry for double-blind, randomised clinical trials 
for the aforementioned agents. 
Inclusion & exclusion criteria 
Blinded, randomized studies comparing one adjunctive pharmacological agent with another or with 
placebo for weight gain and/or metabolic abnormalities will be included. Eligible population consists of 
adult antipsychotic-medicated patients. We will exclude trials studying patients with eating disorders as 
primary diagnoses or comorbidities and studies of children/adolescents. Studies of weight loss agents in 
antipsychotic-medicated healthy volunteers will be excluded, as these findings are less representative of 
real-life conditions.  
Type of intervention 
We are interested in comparing the following pharmacological interventions targeting weight gain and/or 
metabolic abnormalities in antipsychotic-medicated patients: amantadine, aripiprazole, α-lipoic acid, 
betahistine, D-fenfluramine, famotidine, fluvoxamine, liraglutide, melatonin, metformin, naltrexone, 
nizatidine, omega-3 fatty acids, orlistat, reboxetine, sibutramine, topiramate and zonisamide. 
Control 
Placebo or active control with additional agents prescribed for weight gain and/or metabolic 
abnormalities. 
 
Data extraction 
Data will be extracted independently by three of the authors based on PRISMA guidelines statement (12). 
 
Risk of bias assessment 
The studies’ risk of bias will be assessed in accordance to the Cochrane Handbook for Systematic Reviews 
of Interventions (13). 
 
Statistical analysis 
Primary outcomes are efficacy (weight change) and acceptability (treatment discontinuation due to any 
cause). Secondary outcomes include mean overall changes in body mass index, waist circumference, leptin 
serum levels, fasting glucose and insulin, lipids, insulin resistance index (HOMA-IR), glycosylated 
haemoglobin (HbA1c), diastolic and systolic blood pressure.  
Effect measures 
We will analyze the primary outcome using mean difference (MD) or standardised mean difference (SMD) 
depending on whether different measures are used to assess the same outcome. For acceptability of 
interventions we will use odds ratio (OR) for discontinuation rates. For secondary continuous outcomes 
we will either use MD or SMD. 
Network meta-analysis 
We will perform a random-effects NMA to compare pharmacological agents for the primary and secondary 
outcomes. NMA enables the integration of direct and indirect comparisons of the effects of agents 
prescribed for weight loss using a common comparator resulting to more precise treatment effect 
estimates compared with their pairwise meta-analysis counterparts. We will perform NMA using a graph-
theoretical method; the methodology has been found equivalent to other frequentist approaches (14). 
Heterogeneity will be assumed common across different comparisons. We will assess the magnitude of 
heterogeneity by comparing it with derived empirical distributions (15, 16). To assess incoherence we will 
apply a local method comparing direct to indirect evidence in each comparison (17), and a design-by-
treatment interaction model which is a global method to assess incoherence, meaning that it infers about 
the presence of incoherence from any source in the entire network (18, 19). 
Additive model 
In some treatment arms in the network, patients received parallel to the medications lifestyle counselling, 
diet or exercise and others not. To evaluate the influence of individual components on the primary 
outcome–the effects of the pharmacological interventions and that of lifestyle counselling, exercise and 
diet (each at a time) alone- we will implement an additive NMA model assuming that the effect of 
treatment combinations (drug plus lifestyle counselling, exercise or diet) is the sum of the effects of its 
components (20). 
Subgroup, meta-regression and sensitivity analyses 
We will examine the potentially differential effect of the various AP related to the weight gain in several 
subgroup analyses, meta-regressions and sensitivity analyses. If data for conducting a network meta-
regression are not enough, we will conduct a meta-regression based on a pairwise meta-analysis of any 
treatment versus placebo to investigate several demographic characteristics such as age, percentage of 
sex in the study, the duration of the pharmacological intervention and baseline BMI. Further, we will 
conduct subgroup analysis for the groups of obese and non-obese patients based on a BMI cut-off≥ 
30kg/m2. Moreover, based on subgroup analysis, we will assess the role of daily AP dose using 500 
chlorpromazine equivalents (CPZ) as cut-off for low- versus high-dose of AP (21). Moreover, we will control 
for the type of the AP related to the metabolic abnormalities; patients receiving olanzapine and/or 
clozapine will be classified as at high-risk for metabolic abnormalities, whereas patients receiving 
risperidone and/or quetiapine will be classified as at moderate-risk (21, 22). In additional subgroup 
analysis, we will examine the impact of co-medication with known adverse metabolic effects such as mood 
stabilizers, antidepressants and long-acting APs. A further subgroup analysis will be conducted for first-
episode patients (FEP).  
 
Dissemination plans 
Results will be published in a peer-reviewed journal. 
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